SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/20.09.24 | Market Closed - Börse Stuttgart 03:56:44 2024-06-14 am EDT | ||
| 0.007 EUR | +16.67% |
|
| Current month | +133.33% | ||
| 1 month | -12.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 0.007 | +16.67% |
| 24-06-13 | 0.006 | 0.00% |
| 24-06-12 | 0.006 | +100.00% |
| 24-06-11 | 0.003 | -57.14% |
| 24-06-10 | 0.007 | +133.33% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 03:56 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW1YSV |
| ISIN | DE000SW1YSV7 |
| Date issued | 2023-08-07 |
| Strike | 65 $ |
| Maturity | 2024-09-20 (97 Days) |
| Parity | 10 : 1 |
| Emission price | 0.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.48 € |
|---|---|
| Lowest since issue | 0.003 € |
| Spread | 0.013 € |
| Spread % | 65.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Warrants
- Warrant
